Role of novel molecular marker combinations (FN1, MT-1F and TFF3) in the diagnosis of central lymph node metastasis in stage cN0 of smiling papillary thyroid carcinoma

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091815

Enrollment

Unknown

Registered

2024-11-04

Start date

2022-01-01

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid carcinoma

Interventions

Model group:Randomization, no intervention

Validation group:Randomization, no intervention

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients were in general good condition before surgery, without any significant organ diseases that could affect the surgery or prognosis. All patients underwent preoperative neck color Doppler ultrasound, which showed no suspicious signs of central lymph node metastasis. Pathological reports were available for all patients after surgery. All patients signed informed consent forms before enrollment.

Exclusion criteria

Exclusion criteria: A history of major illnesses was present, and preoperative examinations indicated the presence of central lymph node metastasis.

Design outcomes

Primary

Measure	Time frame
the expression of FN1,MT-1F and TFF3;	—

Secondary

Measure	Time frame
Clinical data;	—

Countries

China

Contacts

Public ContactJinqiu Wang

The Fist Affiliated Hospital of Ningbo University

wjqiu1991@163.com+86 139 6782 6211

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026